CGEM:NASDAQ
Cullinan Therapeutics Inc
$9.07
0.00%
(0.00) 1D
Nov 19, 4:00:00 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CGEM...
Mkt. cap
588.83M
Avg. vol.
873.13K
Volume
610.00
52-wk high
$23.19
52-wk low
$8.47
EPS
-$3.32
Beta
-0.03
Shares outstanding
64.92M
No. of employees
109
Mkt. cap
588.83M
Avg. vol.
873.13K
Volume
610.00
52-wk high
$23.19
52-wk low
$8.47
EPS
-$3.32
Beta
-0.03
Shares outstanding
64.92M
No. of employees
109
News stories
From web sources and news partners
ING Sprinters
·
5 hours ago
Uitverkoop AEX Index komt tot een einde
Welingelichte Kringen
·
1 day ago
AEX-index begint hoger, focus op beursgang AI-bedrijf Anthropic
Nieuws.nl
·
2 days ago
AEX-index lager: chipbedrijven dalen voor Nvidia-cijfers
Nieuws.nl
·
3 days ago
AEX-index daalt verder in afwachting van Nvidia-cijfers
About Cullinan Therapeutics Inc
CEO-
Employees109
Founded2016
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitecullinantherapeutics.com
Analyst ratings
Based on 12 analysts giving stock ratings to CGEM in the past 3 months
Strong buy
Buy
12
Hold
0
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for CGEM in the last 3 months.
Highest
Current $9.07
$42.00 (+363.07%)
Average
$34.60 (+281.48%)
Lowest
$27.00 (+197.68%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Boris Peaker JonesTrading | Buy | Maintained | $36.00 | +296.9% | 11/18/2026 |
Sean Laaman Morgan Stanley | Buy | Reiterated | $30.00 | +230.8% | 11/18/2026 |
Robert Burns H.C. Wainwright | Buy | Reiterated | $35.00 | +285.9% | 11/17/2026 |
Unknown Analyst Guggenheim | Buy | Maintained | $35.00 | +285.9% | 11/11/2026 |
David Dai UBS | Buy | Maintained | $27.00 | +197.7% | 11/09/2026 |
Alex Thompson CFA Stifel Nicolaus | Buy | Maintained | $28.00 | +208.7% | 11/09/2026 |
Robert Driscoll Wedbush | Buy | Reiterated | $42.00 | +363.1% | 11/09/2026 |
Julian Harrison BTIG | Buy | Maintained | $41.00 | +352% | 11/10/2026 |
Matt Phipps William Blair | Buy | Maintained | - | - | 11/04/2026 |
Samantha Semenkow Citi | Buy | Maintained | $33.00 | +263.8% | 10/06/2026 |
Phil Nadeau TD Cowen | Buy | Maintained | - | - | 09/24/2026 |
Unknown Analyst Leerink Partners | Buy | Maintained | $39.00 | +330% | 09/16/2026 |
Kaveri Pohlman Clear Street | Buy | Reiterated | $47.00 | +418.2% | 08/14/2026 |
Marc Frahm TD Cowen | Buy | Maintained | - | - | 06/10/2026 |
Soumit Roy JonesTrading | Buy | Maintained | $36.00 | +296.9% | 04/06/2026 |
Bradley Canino Guggenheim | Buy | Reiterated | $30.00 | +230.8% | 03/10/2026 |
Last report
Nov 10, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
-$0.74 / -$0.84
+11.90%beat
arrow_upward
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | - | - | - | - |
Cost of goods sold | - | - | - | - |
Cost of revenue | - | - | - | - |
Research and development expenses | 42.94M | 42.12M | 44.44M | 40.17M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 12.31M | 11.57M | 12.82M | 12.43M |
Operating expense | 55.26M | 53.70M | 57.25M | 52.60M |
Total operating expenses | 55.26M | 53.70M | 57.25M | 52.60M |
Operating income | -55.26M | -53.70M | -57.25M | -52.60M |
Other non operating income | -69.00K | -62.00K | -98.00K | -76.00K |
EBT including unusual items | -50.71M | -49.66M | -53.70M | -49.39M |
EBT excluding unusual items | -50.71M | -49.66M | -53.70M | -49.39M |
Income tax expense | - | - | - | - |
Effective tax rate | - | - | - | - |
Other operating expenses | - | - | - | - |
Net income | -50.71M | -49.66M | -53.70M | -49.39M |
Net profit margin | - | - | - | - |
Earnings per share | -0.77 | -0.75 | -0.81 | -0.74 |
Interest and investment income | 4.62M | 4.10M | 3.65M | 3.29M |
Interest expense | - | - | - | - |
Net interest expenses | 4.62M | 4.10M | 3.65M | 3.29M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -55.18M | -53.62M | -57.18M | -52.55M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events